Some interesting stuff in this interview with SRPT

Some interesting stuff in this interview with SRPT's CEO, like

Quote:

---

BA: It really seems like there’s a new willingness to get these drugs on the market come hell or high water; the FDA and now even NICE appear more flexible than ever before. Is 2016 the year we can say we turned a corner on the regulatory and pricing watchdog side of things in rare disease, where both patients and patients’ groups as well as the biotech/pharmas spending billions on developing medicines are taken ever more into account, rather than just the data handed in for review?

EK: I hope so, because if you think about the FDA, the EMA and the companies, and then you think of the physicians who are like-minded and want to get a therapy onto the market where there are none, generally we all want the same thing.

---

Hmm. Is there any therapy on the market for oral mucositis? What about that awful skin disease HS that causes those abscess tunnels in people's underarms? What about Stage 4 cancer patients whose only hope now might be turning on a cancer-killer gene? hmmmm......